Targeting immunotherapy for amyloidosis

Patent metadata

Field	Value
Publication number	US-10046050-B2
Application number	US-201615052772-A
Country	US
Kind code	B2
Filing date	Feb 24, 2016
Priority date	Aug 26, 2014
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.

First claim

What is claimed is:

1. A method of targeting an amyloid deposit for clearance, comprising:
contacting an amyloid deposit of a first amyloid type with an amyloid-reactive fusion peptide, wherein the amyloid-reactive fusion peptide comprises an amyloid-reactive peptide at least 95% identical to any one of the amino acid sequences set forth as SEQ ID NOS: 1-17 and an HEDT amino acid sequence epitope (SEQ ID NO: 52);
contacting the amyloid-reactive fusion peptide with an antibody or functional fragment thereof, wherein the antibody or functional fragment thereof is immunoreactive to a second amyloid type that is different than the first amyloid type and wherein the HEDT epitope (SEQ ID NO: 52) of the amyloid-reactive fusion peptide directs the antibody or functional fragment thereof to the first amyloid type, thereby targeting the amyloid deposit of the first amyloid type for clearance.

2. The method of claim 1 , wherein targeting the amyloid deposit for clearance results in clearance of the amyloid deposit.

3. The method of claim 1 , wherein the second amyloid type is AA amyloid or AL amyloid and the antibody or functional fragment thereof is immunoreactive to the AA amyloid or AL amyloid.

4. The method of claim 3 , wherein the antibody is a 7D8, 2A4, or 8G9 antibody or functional fragment thereof or variant thereof.

5. The method of claim 4 , wherein the first amyloid type is AH, ATTR, Aß2M, ALect2, Wild type (wt) TTR, AApoAII, AGel, ALys, Afib, ACys, ACal, AMedin, AIAPP, APro, AIns, APrP, or Aβ.

6. The method of claim 1 , wherein the amyloid-reactive peptide comprising the HEDT epitope (SEQ ID NO: 52) is at least 95% identical to the amino acid sequence set forth as SEQ ID NO:26.

7. The method of claim 1 , wherein the amyloid-reactive peptide comprising the HEDT epitope (SEQ ID NO: 52) is at least 95% identical to the amino acid sequence set forth as SEQ ID NO:31.

8. A method for treating amyloidosis in a subject, comprising:
administering to a subject having a first amyloid type an amyloid-reactive fusion peptide, the amyloid-reactive fusion peptide comprising an amyloid-reactive peptide at least 95% identical to any one of the amino acid sequences set forth as SEQ ID NOS: 1-17 and an HEDT amino acid sequence epitope (SEQ ID NO: 52);
administering to the subject an antibody or functional fragment thereof that is immunoreactive to a second amyloid type and that binds to the HEDT epitope (SEQ ID NO: 52) of the amyloid-reactive fusion peptide, wherein administration of the antibody or functional fragment thereof to the subject targets the first amyloid type for clearance, the second amyloid type being different than the first amyloid type.

9. The method of claim 8 , further comprising testing the subject to determine whether the subject has amyloidosis before administering the amyloid-reactive fusion peptide or the antibody or functional fragment thereof.

10. The method of claim 8 , wherein the second amyloid type is AA amyloid or AL amyloid and the antibody or functional fragment thereof is immunoreactive to the AA amyloid or AL amyloid.

11. The method of claim 10 , wherein administration of the antibody or functional fragment thereof results in clearance of an amyloid deposit comprising the first amyloid type.

12. The method of claim 10 , wherein the antibody is a 7D8, 2A4, or 8G9 antibody or functional fragment thereof or variant thereof.

13. The method of claim 10 , wherein the first amyloid type is AH, ATTR, Aß2M, Wild type (wt) TTR, AApoAII, AGel, ALys, ALect2, Afib, ACys, ACal, AMedin, AIAPP, APro, AIns, APrP, or Aβ.

14. The method of claim 8 , wherein the amyloid-reactive fusion peptide comprising the HEDT sequence (SEQ ID NO: 52) is at least 95% identical the amino acid sequence set forth as SEQ ID NO:26.

15. A method of targeting an antibody or functional fragment thereof to an amyloid deposit in a subject, comprising:
administering to a subject having a first amyloid type an effective amount of an amyloid-reactive fusion peptide, wherein the amyloid-reactive fusion peptide comprises an amyloid-reactive peptide comprising at least 95% identity to any one of the amino acid sequences set forth as SEQ ID NOS: 1-17 and an HEDT epitope (SEQ ID NO: 52), the HEDT epitope (SEQ ID NO: 52) comprising binding affinity for an antibody or functional fragment thereof that is immunoreactivity to a second amyloid type that is different from the first amyloid type; and,
administering to the subject an effective amount of the antibody or functional fragment thereof, thereby targeting the antibody or functional fragment thereof to the first amyloid type.

16. The method of claim 15 , wherein targeting the antibody or functional fragment thereof to the first amyloid type results in clearance of an amyloid deposit comprising the first amyloid type.

17. The method of claim 15 , wherein the second amyloid type is AA amyloid or AL amyloid.

18. The method of claim 15 , wherein the first amyloid type is AH, ATTR, Aß2M, Wild type (wt) TTR, AApoAI, AGel, ALys, ALect2, Afib, ACys, ACal, AMedin, AIAPP, APro, AIns, APrP, or Aβ.

19. The method of claim 15 , wherein the amyloid-reactive fusion peptide is at least 95% identical the amino acid sequence set forth as SEQ ID NO:26.

20. The method of claim 15 , wherein the amyloid-reactive fusion peptide is at least 95% identical the amino acid sequence set forth as SEQ ID NO:31.

Assignees

• Univ Tennessee Res Found
• Univ Of Tenessee Research Foundation

Inventors

• Wall Jonathan S
• Kennel Stephen J
• Foster James S

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• G01N33/53

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title

• A61K47/6891

  Pre-targeting systems involving an antibody for targeting specific cells · CPC title